Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences — Stockholders' equity by Quarter
Alpine Immune Sciences — Stockholders' equity ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences — Stockholders' equity: $333M in Q1 2024, up 96.2% from a year earlier. That is the highest of the 25 quarters on record here. No newer figure appears in the documents we track.
Where the Q1 2024 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences — Stockholders' equity ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2024 | Mar 31, 2024 | 333 | +96.2% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 328 | +82.8% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 162 | -11.2% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 169 | +70.2% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 170 | +46.9% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 179 | +48.4% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 182 | +48.2% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 99.5 | +127.1% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 115 | +116.6% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 121 | +94.5% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 123 | +82.0% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 43.8 | +170.1% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 53.3 | +114.4% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 62.2 | +110.9% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 67.5 | +93.7% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 16.2 | -64.3% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 24.9 | -56.1% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 29.5 | -33.9% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 34.8 | -36.6% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 45.4 | -31.8% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 56.6 | -23.4% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 44.6 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | 55.0 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | 66.6 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | 73.9 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences — Stockholders' equity ($M), quarterly Q1 2018–Q1 2024 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-equity
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.